Liquidia Technologies
  |   |   |
   Home  |  Site Map  |  Contact Us  
  

Company

Overview
Management Team
Board of Directors
Investors
Partnerships
Contact

Management Team

Neal Fowler, Chief Executive Officer
Mr. Fowler joined Liquidia in 2008 after seven successful years at Johnson & Johnson (J&J). While at J&J, Neal served as President of Centocor, Inc., a multi-billion dollar subsidiary focused on development and commercialization of industry leading biomedicines used in the treatment of chronic inflammatory diseases. At Centocor, Mr. Fowler prepared the company for the launch of two potential blockbuster products and continued the company's legacy of double-digit growth for their flagship product REMICADE® (infliximab). Prior to Centocor, Mr. Fowler was president of Ortho-McNeil Neurologics Inc. and vice president of the central nervous system franchise at Ortho-McNeil Pharmaceuticals. Mr. Fowler joined J&J after a successful 13-year career at Eli Lilly and Company where he held a variety of sales, marketing and business development roles with increasing responsibilities in both the pharmaceutical and medical divisions. Mr. Fowler is a native of Raleigh, NC and received a Bachelor of Science degree in Pharmacy and Masters of Business Administration from the University of North Carolina at Chapel Hill (UNC-CH).

Tim Albury, Chief Financial Officer
Before joining Liquidia in 2013, Mr. Albury served as the Chief Financial Officer of Osmotica Pharmaceutical Corp., a multinational specialty pharmaceutical company and one of the world leaders in osmotic drug delivery with several products commercialized. Prior to that, Mr. Albury served as the Chief Financial Officer for KBI Biopharma, a world leader in contract biopharmaceutical drug development. Earlier in his career, Mr. Albury served as the Chief Financial Officer of Ardent Pharmaceuticals, a specialty pharmaceutical company focused on the development of a broad drug portfolio based upon delta receptor pharmacology. Prior to these industry roles, Mr. Albury served for 12 years in the Assurance & Business Advisory practice of Arthur Andersen, focused on the life sciences industry and healthcare. Mr. Albury is a Certified Public Accountant in North Carolina and Florida. He earned his master's degree in Professional Accountancy at the University of Miami.

Frank J. Malinoski, M.D., Ph.D., Chief Medical Officer
Dr. Malinoski has more than 20 years of executive experience in the biotech and pharmaceutical industries, including work in clinical and global business development, regulatory evaluation, and post-approval oversight for numerous vaccines and immunotherapy products. Dr. Malinoski has extensive background in the fields of vaccines, immunology, oncology, infectious disease and other key therapeutic areas. Prior to joining Liquidia in 2010, Dr. Malinoski held senior positions in clinical research, business development, and medical affairs at Wyeth, MedImmune, Nabi and several other biopharmaceutical companies. His responsibilities included pre-licensure clinical evaluation and post-licensure activities in support of vaccines and immunotherapy, and his efforts contributed to the licensure of Prevnar, Meningitec, and Tetramune vaccines. Dr. Malinoski received his B.A. from Colby College, his M.D. from Albany Medical College, and his Ph.D. in microbiology from Rutgers University.

Benjamin Yerxa, Ph.D., Chief Scientific Officer
Dr. Yerxa joined Liquidia from Clearside Biomedical, an early stage ophthalmic startup. Prior to Clearside, Dr. Yerxa was the Executive Vice President and Chief, Research & Development of Inspire Pharmaceuticals, a top ranked publicly traded biotech company acquired by Merck & Co., Inc. During his time at Inspire, Dr. Yerxa helped the company build and commercialize a portfolio of innovative new products and provided critical support through multiple rounds of financing, including the company’s initial public offering (IPO).  Throughout his 20-year career in the pharmaceutical and biotechnology industry, Dr. Yerxa has been involved with the discovery and development of several investigational new drugs (INDs), phase 3 clinical programs, new drug applications (NDAs) and drug approvals.  His experience spans a variety of therapeutic areas including ophthalmology, pulmonary, cardiovascular and HIV.  Dr. Yerxa has more than 50 U.S. patents to his name, led a variety of licensing deals including technology transfers and manufacturing agreements and has built several R&D and corporate functions from inception.

Ash Nijhawan, Vice President, Business Development
Mr. Nijhawan joined Liquidia in 2010 from Schering-Plough, Corp. where he was responsible for all aspects of merger & acquisition, licensing, & divestiture transactions. Prior to joining Schering Plough, he was a Director in Pfizer's Management Science Group where he worked closely with a team to identify, evaluate, and support the negotiation of in-license drug candidates. Prior to joining Pfizer, Mr. Nijhawan spent two years at Stern Stewart & Company and started his career at General Electric Company. Mr. Nijhawan has a M.B.A. from New York University and a B.S. in Electrical Engineering from North Carolina State University.

 

 

© 2014 Liquidia Technologies | PO Box 110085 | Research Triangle Park, NC 27709 | P.919.328.4400 | F.919.328.4402 | email: info@liquidia.com